CL2022001545A1 - Composiciones y métodos para tratar y prevenir la influenza - Google Patents
Composiciones y métodos para tratar y prevenir la influenzaInfo
- Publication number
- CL2022001545A1 CL2022001545A1 CL2022001545A CL2022001545A CL2022001545A1 CL 2022001545 A1 CL2022001545 A1 CL 2022001545A1 CL 2022001545 A CL2022001545 A CL 2022001545A CL 2022001545 A CL2022001545 A CL 2022001545A CL 2022001545 A1 CL2022001545 A1 CL 2022001545A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- compositions
- treating
- preventing influenza
- influenza
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946772P | 2019-12-11 | 2019-12-11 | |
| US202062985623P | 2020-03-05 | 2020-03-05 | |
| US202063028938P | 2020-05-22 | 2020-05-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001545A1 true CL2022001545A1 (es) | 2023-03-24 |
Family
ID=74046215
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001545A CL2022001545A1 (es) | 2019-12-11 | 2022-06-09 | Composiciones y métodos para tratar y prevenir la influenza |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230257449A1 (https=) |
| EP (1) | EP4073107A1 (https=) |
| JP (1) | JP2023506156A (https=) |
| KR (1) | KR20220113749A (https=) |
| CN (1) | CN115551885A (https=) |
| AU (1) | AU2020403133A1 (https=) |
| BR (1) | BR112022011350A2 (https=) |
| CA (1) | CA3164230A1 (https=) |
| CL (1) | CL2022001545A1 (https=) |
| IL (1) | IL293804A (https=) |
| MX (1) | MX2022007207A (https=) |
| WO (1) | WO2021119467A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| US11230593B2 (en) | 2019-03-25 | 2022-01-25 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| CN118388650B (zh) * | 2024-06-28 | 2024-08-27 | 杭州赛基生物科技有限公司 | 一种抗CD235a单克隆抗体及其制备方法和应用 |
| CN119901847B (zh) * | 2025-04-01 | 2025-06-27 | 天津辰欣药物研究有限公司 | 一种抗病毒新药中间体中相关异构体杂质的质量控制方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| EP1553975B8 (en) | 2002-09-27 | 2023-04-12 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| WO2005063815A2 (en) | 2003-11-12 | 2005-07-14 | Biogen Idec Ma Inc. | Fcϝ receptor-binding polypeptide variants and methods related thereto |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| US20090081193A1 (en) | 2006-08-14 | 2009-03-26 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| US20090269342A1 (en) | 2006-08-14 | 2009-10-29 | Massachusetts Institute Of Technology | Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto |
| WO2008073161A2 (en) | 2006-08-14 | 2008-06-19 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
| EP2158318A2 (en) | 2007-05-14 | 2010-03-03 | Biogen Idec MA, Inc. | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| RU2010127156A (ru) * | 2007-12-06 | 2012-01-20 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Антитела против вируса гриппа и их применение |
| US8871207B2 (en) | 2008-07-25 | 2014-10-28 | Humabs, LLC | Neutralizing anti-influenza A virus antibodies and uses thereof |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| AU2011210840B2 (en) | 2010-01-27 | 2014-12-11 | Massachusetts Institute Of Technology | Engineered polypeptide agents for targeted broad spectrum influenza neutralization |
| WO2012072788A1 (en) * | 2010-12-02 | 2012-06-07 | Mab-Factory Gmbh | Vaccine against influenza h5n1 viruses, medicament and treatment of h5n1 viral infections |
| AU2011373387B2 (en) * | 2011-07-18 | 2017-06-29 | Institute For Research In Biomedicine | Neutralizing anti-influenza A virus antibodies and uses thereof |
| SG11201406769RA (en) | 2012-05-10 | 2014-11-27 | Massachusetts Inst Technology | Agents for influenza neutralization |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| ES2833230T3 (es) * | 2014-05-13 | 2021-06-14 | Univ Pennsylvania | Composiciones que comprenden AVV que expresan construcciones y usos de doble anticuerpo del mismo |
| KR102668588B1 (ko) * | 2015-04-08 | 2024-05-22 | 다나-파버 캔서 인스티튜트 인크. | 인간화된 인플루엔자 모노클로날 항체 및 그의 사용 방법 |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| HRP20260151T1 (hr) | 2016-08-02 | 2026-03-27 | Visterra, Inc. | Modificirani polipeptidi i njihova uporaba |
-
2020
- 2020-12-11 WO PCT/US2020/064573 patent/WO2021119467A1/en not_active Ceased
- 2020-12-11 CA CA3164230A patent/CA3164230A1/en active Pending
- 2020-12-11 BR BR112022011350A patent/BR112022011350A2/pt unknown
- 2020-12-11 IL IL293804A patent/IL293804A/en unknown
- 2020-12-11 JP JP2022535124A patent/JP2023506156A/ja active Pending
- 2020-12-11 EP EP20829493.4A patent/EP4073107A1/en not_active Withdrawn
- 2020-12-11 US US17/783,966 patent/US20230257449A1/en not_active Abandoned
- 2020-12-11 MX MX2022007207A patent/MX2022007207A/es unknown
- 2020-12-11 KR KR1020227023210A patent/KR20220113749A/ko active Pending
- 2020-12-11 CN CN202080096260.7A patent/CN115551885A/zh active Pending
- 2020-12-11 AU AU2020403133A patent/AU2020403133A1/en active Pending
-
2022
- 2022-06-09 CL CL2022001545A patent/CL2022001545A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020403133A1 (en) | 2022-06-23 |
| IL293804A (en) | 2022-08-01 |
| EP4073107A1 (en) | 2022-10-19 |
| CN115551885A (zh) | 2022-12-30 |
| JP2023506156A (ja) | 2023-02-15 |
| KR20220113749A (ko) | 2022-08-16 |
| MX2022007207A (es) | 2022-07-12 |
| CA3164230A1 (en) | 2021-06-17 |
| BR112022011350A2 (pt) | 2022-08-23 |
| WO2021119467A1 (en) | 2021-06-17 |
| US20230257449A1 (en) | 2023-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022001545A1 (es) | Composiciones y métodos para tratar y prevenir la influenza | |
| CO2018000410A2 (es) | Moléculas de anticuerpo que se unen a cd79 | |
| MX2014013668A (es) | Nuevos agentes de union a ha. | |
| CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| BR112021019748A2 (pt) | Degradadores de stat e usos dos mesmos | |
| CL2019002196A1 (es) | Anticuerpos humanos neutralizantes que se unen a hemaglutinina de influenza a. (divisional solicitud 201701610) | |
| CO2018000211A2 (es) | Moléculas de anticuerpo que se unen a cd45 | |
| CO2020005981A2 (es) | Anticuerpos anti-tau y uso de los mismos | |
| CL2018002694A1 (es) | Moleculas de anticuerpos que se unen a lag-3 y usos de las mismas (divisional solicitud 201602112) | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| CL2018002874A1 (es) | Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016). | |
| BR112022012410A2 (pt) | Degradadores smarca e usos dos mesmos | |
| MX2024006565A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
| BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
| MX2021004687A (es) | Anticuerpo anti-influenza a neutralizantes y usos de los mismos. | |
| CR20110084A (es) | Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| DOP2017000236A (es) | Neutralización del virus chikungunya mediada por anticuerpos | |
| CO2020013833A2 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| MX2017015189A (es) | Neutralizacion de moleculas de union anti-influenza y usos de las mismas. | |
| CL2021000849A1 (es) | Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999) | |
| BR112018008900A2 (pt) | composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas | |
| MX2024006290A (es) | Anticuerpos monoclonales de adn dirigidos al virus de la influenza. |